Which pneumococcal conjugate vaccine does ACIP recommend for U.S. children now?
The ACIP recommends the 20-valent pneumococcal conjugate vaccine for children in the United States 2. This recommendation updates previous guidance that favored the 15-valent version 3. The 20-valent vaccine covers more serotypes than earlier options, providing broader protection against pneumococcal disease 2.
What the research says
ACIP updated its guidance to recommend the 20-valent pneumococcal conjugate vaccine for children 2. This change reflects a shift from earlier recommendations that supported the 15-valent vaccine 3. The 20-valent formulation includes additional serotypes not found in the 15-valent version, expanding the range of bacteria strains it can prevent 2.
Previously, the ACIP recommended the 15-valent vaccine for U.S. children 3. This earlier recommendation covered a specific set of serotypes but was superseded by the newer 20-valent option 2. The transition to the 20-valent vaccine ensures that children receive protection against a wider variety of pneumococcal strains that cause infection 2.
Earlier reports detailed the use of the 13-valent vaccine for children, which was the standard before the 15-valent and 20-valent options became available 8. The current recommendation for the 20-valent vaccine represents the latest standard of care for preventing pneumococcal disease in this age group 2.
What to ask your doctor
- Does my child need the 20-valent pneumococcal conjugate vaccine based on their age and health history?
- How does the 20-valent vaccine differ from the older 15-valent or 13-valent vaccines?
- What is the recommended schedule for giving pneumococcal vaccine doses to my child?
- Are there any side effects I should watch for after my child receives the vaccine?
This question is drawn from common patient questions about Pediatrics and answered using cited medical research. We do not provide individualized advice.